ProCE Banner Activity


Advances in Ovarian Cancer and Navigating the Evolving Therapy Choices


In this video, an expert describes recent updates in the management of ovarian cancer from newly diagnosed disease through relapsed/refractory disease, along with strategies for monitoring and managing adverse events associated with treatment.

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: June 19, 2023

Expiration: June 18, 2024



Stephanie Shuey

Stephanie Shuey, PharmD, BCOP

Clinical Pharmacist- Gynecologic Oncology
Department of Pharmacy
Duke University Medical Center
Durham, North Carolina 

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from GSK and Novocure, Inc.


Novocure, Inc


Clinical Care Options, LLC

ProCE Banner

Target Audience

The target audience for this activity is pharmacists—including specialty, managed care, and clinical pharmacists—who care for patients with ovarian cancer as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners about the optimal and equitable management of treatment-naive and relapsed ovarian cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize clinical data on the role of PARP inhibitors as single agents or in combination therapies for ovarian cancer

  • Develop individualized treatment strategies for patients with newly diagnosed and recurrent or relapsed ovarian cancer that incorporate novel therapies and combination strategies


ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Stephanie Shuey, PharmD, BCOP

Clinical Pharmacist- Gynecologic Oncology
Department of Pharmacy
Duke University Medical Center
Durham, North Carolina 

Stephanie Shuey, PharmD, BCOP: consultant/advisor/speaker: GlaxoSmithKline, Immunogen.

The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-024-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 0.5 contact hours (0.050 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65 or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.